BOXED O
WARNING O
: O
WARNING O
: O
ENDOMETRIAL O
CANCER O
, O
CARDIOVASCULAR O
DISORDERS O
, O
BREAST O
CANCER O
AND O
PROBABLE O
DEMENTIA O
WARNING O
: O
ENDOMETRIAL O
CANCER O
, O
CARDIOVASCULAR O
DISORDERS O
, O
BREAST O
CANCER O
AND O
PROBABLE O
DEMENTIA O
EXCERPT O
: O
WARNING O
: O
ENDOMETRIAL O
CANCER O
, O
CARDIOVASCULAR O
DISORDERS O
, O
BREAST O
CANCER O
AND O
PROBABLE O
DEMENTIA O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

Estrogen-Alone O
Therapy O
* O
There O
is O
an O
increased O
risk O
of O
endometrial O
cancer O
in O
a O
woman O
with O
a O
uterus O
who O
uses O
unopposed O
estrogens O
( O
5.2 O
) O
* O
Estrogen-alone O
therapy O
should O
not O
be O
used O
for O
the O
prevention O
of O
cardiovascular O
disease O
or O
dementia O
( O
5.1 O
, O
5.3 O
) O
* O
Women O
's O
Health O
Initiative O
( O
WHI O
) O
estrogen-alone O
substudy O
reported O
increased O
risks O
of O
stroke O
and O
deep O
vein O
thrombosis O
( O
DVT O
) O
( O
5.1 O
) O
* O
The O
WHI O
Memory O
Study O
( O
WHIMS O
) O
estrogen-alone O
ancillary O
study O
of O
WHI O
reported O
an O
increased O
risk O
of O
probable O
dementia O
in O
postmenopausal O
women O
65 O
years O
of O
age O
and O
older O
( O
5.3 O
) O
Estrogen O
Plus O
Progestin O
Therapy O
* O
Estrogen O
plus O
progestin O
therapy O
should O
not O
be O
used O
for O
the O
prevention O
of O
cardiovascular O
disease O
or O
dementia O
( O
5.1 O
, O
5.3 O
) O
* O
The O
WHI O
estrogen O
plus O
progestin O
substudy O
reported O
increased O
risks O
of O
stroke O
, O
DVT O
, O
pulmonary O
embolism O
( O
PE O
) O
, O
and O
myocardial O
infarction O
( O
MI O
) O
( O
5.1 O
) O
* O
The O
WHI O
estrogen O
plus O
progestin O
substudy O
reported O
increased O
risks O
of O
invasive O
breast O
cancer O
( O
5.2 O
) O
* O
The O
WHIMS O
estrogen O
plus O
progestin O
ancillary O
study O
of O
WHI O
reported O
an O
increased O
risk O
of O
probable O
dementia O
in O
postmenopausal O
women O
65 O
years O
of O
age O
and O
older O
( O
5.3 O
) O
Estrogen-Alone O
Therapy O
Endometrial O
Cancer O
There O
is O
an O
increased O
risk O
of O
endometrial B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
in O
a O
woman O
with O
a O
uterus O
who O
uses O
unopposed O
estrogens O
. O

Adding O
a O
progestin O
to O
estrogen O
therapy O
has O
been O
shown O
to O
reduce O
the O
risk O
of O
endometrial B-NonOSE_AE
hyperplasia I-NonOSE_AE
, O
which O
may O
be O
a O
precursor O
to O
endometrial B-NonOSE_AE
cancer I-NonOSE_AE
. O

Adequate O
diagnostic O
measures O
, O
including O
directed O
or O
random O
endometrial O
sampling O
when O
indicated O
, O
should O
be O
undertaken O
to O
rule O
out O
malignancy B-Not_AE_Candidate
in O
postmenopausal B-Not_AE_Candidate
women O
with O
undiagnosed O
persistent O
or O
recurring O
abnormal B-Not_AE_Candidate
genital I-Not_AE_Candidate
bleeding I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Cardiovascular O
Disorders O
and O
Probable O
Dementia O
Estrogen-alone O
therapy O
should O
not O
be O
used O
for O
the O
prevention O
of O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
dementia B-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
, O
5.3 O
) O
, O
and O
Clinical O
Studies O
( O
14.5 O
, O
14.6 O
) O
] O
. O

The O
Women O
's O
Health O
Initiative O
( O
WHI O
) O
estrogen-alone O
substudy O
reported O
increased O
risks O
of O
stroke B-OSE_Labeled_AE
and O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DVT I-OSE_Labeled_AE
) O
in O
postmenopausal B-Not_AE_Candidate
women O
( O
50 O
to O
79 O
years O
of O
age O
) O
during O
7.1 O
years O
of O
treatment O
with O
daily O
oral O
conjugated O
estrogens O
( O
CE O
) O
[ O
0.625 O
mg O
] O
-alone O
, O
relative O
to O
placebo O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
and O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

The O
WHI O
Memory O
Study O
( O
WHIMS O
) O
estrogen-alone O
ancillary O
study O
of O
WHI O
reported O
an O
increased O
risk O
of O
developing O
probable O
dementia B-OSE_Labeled_AE
in O
postmenopausal B-Not_AE_Candidate
women O
65 O
years O
of O
age O
or O
older O
during O
5.2 O
years O
of O
treatment O
with O
daily O
CE O
( O
0.625 O
mg O
) O
-alone O
, O
relative O
to O
placebo O
. O

It O
is O
unknown O
whether O
this O
finding O
applies O
to O
younger O
postmenopausal B-Not_AE_Candidate
women O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
, O
and O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

In O
the O
absence O
of O
comparable O
data O
, O
these O
risks O
should O
be O
assumed O
to O
be O
similar O
for O
other O
doses O
of O
CE O
and O
other O
dosage O
forms O
of O
estrogens O
. O

Estrogens O
with O
or O
without O
progestins O
should O
be O
prescribed O
at O
the O
lowest O
effective O
doses O
and O
for O
the O
shortest O
duration O
consistent O
with O
treatment O
goals O
and O
risks O
for O
the O
individual O
woman O
. O

Estrogen O
Plus O
Progestin O
Therapy O
Cardiovascular O
Disorders O
and O
Probable O
Dementia O
Estrogen O
plus O
progestin O
therapy O
should O
not O
be O
used O
for O
the O
prevention O
of O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
dementia B-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
, O
5.3 O
) O
, O
and O
Clinical O
Studies O
( O
14.5 O
, O
14.6 O
) O
] O
. O

The O
WHI O
estrogen O
plus O
progestin O
substudy O
reported O
increased O
risks O
of O
DVT B-NonOSE_AE
, O
pulmonary B-NonOSE_AE
embolism I-NonOSE_AE
( I-NonOSE_AE
PE I-NonOSE_AE
) O
, O
stroke B-NonOSE_AE
and O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
( I-NonOSE_AE
MI I-NonOSE_AE
) O
in O
postmenopausal B-Not_AE_Candidate
women O
( O
50 O
to O
79 O
years O
of O
age O
) O
during O
5.6 O
years O
of O
treatment O
with O
daily O
oral O
CE O
( O
0.625 O
mg O
) O
combined O
with O
medroxyprogesterone O
acetate O
( O
MPA O
) O
[ O
2.5 O
mg O
] O
, O
relative O
to O
placebo O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
and O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

The O
WHIMS O
estrogen O
plus O
progestin O
ancillary O
study O
of O
the O
WHI O
, O
reported O
an O
increased O
risk O
of O
developing O
probable O
dementia B-NonOSE_AE
in O
postmenopausal B-Not_AE_Candidate
women O
65 O
years O
of O
age O
or O
older O
during O
4 O
years O
of O
treatment O
with O
daily O
CE O
( O
0.625 O
mg O
) O
combined O
with O
MPA O
( O
2.5 O
mg O
) O
, O
relative O
to O
placebo O
. O

It O
is O
unknown O
whether O
this O
finding O
applies O
to O
younger O
postmenopausal B-Not_AE_Candidate
women O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
, O
and O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

Breast O
Cancer O
The O
WHI O
estrogen O
plus O
progestin O
substudy O
also O
demonstrated O
an O
increased O
risk O
of O
invasive O
breast B-NonOSE_AE
cancer I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
, O
and O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

In O
the O
absence O
of O
comparable O
data O
, O
these O
risks O
should O
be O
assumed O
to O
be O
similar O
for O
other O
doses O
of O
CE O
and O
MPA O
, O
and O
other O
combinations O
and O
dosage O
forms O
of O
estrogens O
and O
progestins O
. O

Estrogens O
with O
or O
without O
progestins O
should O
be O
prescribed O
at O
the O
lowest O
effective O
doses O
and O
for O
the O
shortest O
duration O
consistent O
with O
treatment O
goals O
and O
risks O
for O
the O
individual O
woman O
. O

